Novartis Adds To Dermatology Portfolio
Novartis has acquired 2012 Pfizer-spinout company Ziarco, adding a Phase II selective histamine H4 receptor antagonist for eczema to its dermatology portfolio.
Novartis has acquired 2012 Pfizer-spinout company Ziarco, adding a Phase II selective histamine H4 receptor antagonist for eczema to its dermatology portfolio.